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1. Introduction 
Within the complex array of numerous immunological processes that protect the host from 
invading pathogens and at the same time avoid excessive immune reactions with induction 
and maintenance of tolerance to self, the dendritic cells (DCs) have been designated as 
central players. Discovered and morphologically described by Steinman and Cohn almost 30 
years ago, DCs have gained an ever-increasing interest from the scientific community 
(Steinman, Topliss et al. 1973). This has been even more pronounced throughout the last 
decade with the discovery that DCs not only serve as primary initiators of antigen (Ag)-
specific immune responses, but can also induce immunological tolerance and contribute to 
immune homeostasis maintenance by various mechanisms, including induction of 
regulatory T cells (Treg) (Steinman, Hawiger et al. 2003). Indeed, the DCs possess a unique 
set of biological tools that allows them to present Ag information to effector cells of the 
immune system in a way to promote tolerance induction by functional mechanisms such as 
T-cell anergy, deletion, apoptosis and instruction of different Treg types. Direct delivery of 
tolerogenic signals by DCs, most commonly to respective Ag-specific T cells, is in a great 
way determined by the DCs preliminary activation state, which itself is orchestrated by 
various environments that DCs find themselves in under both physiological and 
pathophysiological conditions. Today it is well-documented, that a number of 
immunosuppressive factors, either related to specific tissue microenvironments, microbial 
components or pharmacological immunosuppressants, can act on DCs in a way to cause 
their alternative activation or tolerogenic state (Weiner 2001; Hackstein and Thomson 2004; 
Rutella, Danese et al. 2006). In addition to immature (iDCs) which are known to act in an 
immunosuppressive fashion, the tolerogenic DCs (TDCs) can be said to do the same but in 
an even more efficient manner. Whereas tolerance induction by iDCs seems to rely mostly 
on insufficient delivery of co-stimulatory signals, TDCs express more elements of active 
tolerance induction, including surface inhibitory molecules and production of anti-
inflammatory cytokines, that are expressed depending on the nature of DC activation 
and/or development. 
With DCs able to achieve greatly opposing states regarding their immunostimulatory status, 
together with the notion of manipulating DC function in the lab, scientists have put ongoing 
efforts into resolving the underlying mechanisms of DC-mediated tolerance induction. The 
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development of quality protocols for in vitro/ex vivo generation of efficient TDCs still 
remains a hot topic. We are now witnessing the beginning of first clinical trials involving 
TDCs for the treatment of immune-mediated diseases and can expect a lot of development 
in this field in the near future. In this chapter, we will focus on up-to-date discoveries 
regarding the nature of TDCs and how this knowledge can be exploited for the benefit of 
successful future treatments of various immune-mediated disorders. 
2. Role of DCs in immunity and immune homeostasis 
In a sense of immunological function by definition, the role of DCs in general is that of a 
sentinel, which literally means that they are rather the carriers of antigenic information, 
rather than being effector cells per se. In the body, under physiological conditions, the DCs 
predominantly reside in tissues at body surfaces, where their main task is to actively sample 
the environment and process both endogenous and exogenous Ags, with the aim to be 
presented to Ag-specific T cells in secondary lymphoid tissues (Banchereau and Steinman 
1998). As Ags are internalized and processed, they are targeted to MHC (major 
histocompatibility complex) class II-positive lysosomes. There, they are not immediately 
loaded into MHC II-peptide complexes, but are retained for later use as immunogenic 
peptides (Inaba, Turley et al. 2000). The activation state in which these DCs excel with their 
unique Ag-processing machinery is called an immature state. There are many specific 
characteristics that separate iDCs from their fully activated state that DCs encompass after 
full and optimal maturation process. Besides the ability of endocytosing Ag material, iDCs 
are characterized by low expression of co-stimulatory molecules, low or absent production 
of pro-inflammatory cytokines and low allo-stimulatory capacity, the latter also being 
associated with relatively low expression of MHC class I and II molecules on DC surface. It 
is thus said that iDCs, when in contact with the responding T cells, can induce tolerogenic 
outcomes via elements of passive tolerance (Lutz and Schuler 2002). In other words, the lack 
of co-stimulatory signals derived from iDCs, particularly signal 2 (co-stimulatory molecules) 
and signal 3 (pro-inflammatory cytokines), results in failure to initiate effector immune 
responses, but induce anergy and also Tregs instead. 
In contrast, when iDCs are activated by various ligands that bind pattern recognition 
receptors or PRRs (e.g. LPS for toll-like receptor (TLR)4, viral RNA for TLR3, muramyl 
dipeptide (MDP) for nucleotide oligomerization domain (NOD) receptors, etc.) they change 
drastically in both their appearance and function (Banchereau and Steinman 1998; Mellman 
and Steinman 2001). This so called mature DC state, has for a long time, together with 
immature state on the other side, defined what has been understood by immunologists as 
two existing and opposing states of DC activation (Cella, Sallusto et al. 1997). Indeed, after 
maturation the function of DCs changes greatly towards the presentation of Ags processed 
under physiological conditions with the main task to induce effector T cell responses of 
different types including Th1, Th2 and Th17 (Lanzavecchia and Sallusto 2001; Moser 2003; 
Kadowaki 2007). This ability is associated with a number of morphological and 
phenotypical changes. In this manner, upon PRR activation by respective ligands, maturing 
DCs seize their Ag-sampling function and begin to express peptide-MHC complexes on 
their surface. In addition, down-regulation of tissue-homing chemokine receptors such as 
CCR1, CCR2 and CCR5 is initiated and they begin to express CCR7 which guides maturing 
DCs to lymph nodes. Mature DCs generally express high levels of MHC molecules and 
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CD80, CD86, other co-stimulatory molecules, however they influence the T cell 
differentiation towards various effector types in a great way by the so called third signal, 
which represents the cytokine-producing profile of DCs. The latter is in great way 
dependant on the manner in which the DCs were activated, in other words, what type of 
danger signal induced their maturation. In response to certain bacteria, viruses and 
parasites, the DCs are instructed to produce large quantities of IL-12, as well as type I 
interferons (IFNs) (Banchereau and Steinman 1998; Pulendran, Palucka et al. 2001). Such 
DCs have the capacity to orchestrate Th1-type effector T cells, which later assist in the 
activation of macrophages and cytotoxic CD8+ T cells to kill respective pathogens that were 
encountered. Extracellular pathogens, for example helminthes, activate DCs in a way that 
they produce lower quantities of IL-12, but on the other hand increased amounts of IL-10 
and IL-4, which can then shift the balance towards Th2 effectors (MacDonald and Maizels 
2008). Other factors besides signal 3-mediators have been found recently to contribute to 
Th2 development. Indeed, the co-stimulator OX40L expressed by DCs has been recently 
found important (Blazquez and Berin 2008). It also must be noted, that induction of a Th2 
profile is also significantly regulated by environmental instruction such as specific tissue 
derived factors and lipid mediators including prostaglandin D and E (MacDonald and 
Maizels 2008). Next, stimulation of DCs through the NOD2 receptor instructs DCs to 
produce IL-1, IL-6 and IL-23, which then induce IL-17 production and the differentiation of 
Th17 effector T cells (van Beelen, Zelinkova et al. 2007). 
Besides effective Ag-sampling, the ability to induce immunosuppressive outcomes is 
another vital attribute of iDCs, that has been recently appointed with potential importance 
in the induction and maintenance of so-called peripheral tolerance. When we question the 
immunogenicity of a specific Ag, be it e.g. a protein or a peptide, we soon encounter a 
complex issue consisting of many factors that are implicated in the way in which such Ag is 
presented to cells of the immune system. Indeed, many of these factors are directly 
associated or governed by DCs as professional antigen-presenting cells (APCs), as they can 
directly shape the way in which a naïve T cell “sees” the Ag itself. While strong Th1- or Th2-
type immune responses can only be induced by mature DCs (mDCs), iDCs can present the 
same Ag to induce tolerance, and in the peripheral immune networks, the latter seems to be 
of great importance. Just recently, there were theoretical challenges to such beliefs, since 
iDCs are known to reside mainly in tissues and do not express proper homing receptors, 
such as the chemokine receptor CCR7 and the ability to respond to lymph node homing 
ligands CCL19 and CCL21, that would guide these cells to secondary lymph nodes to allow 
sufficient DC-T cell contact. In addition, insufficient Ag-presentation on the surface of iDCs 
would hamper the recognition of Ag by T cells (Inaba, Turley et al. 2000). However, there is 
now proof that iDCs can migrate via afferent lymph and that they contribute significantly to 
peripheral tolerance to self, by up-take of apoptotic material from normal cell turnover. 
Antigenic material from apoptotic cells is then presented to naïve T cells by such iDCs 
which leads to tolerance induction due to lack of co-stimulation (Steinman, Turley et al. 
2000). Thus iDCs constantly traffic from tissues to secondary lymph nodes carrying self-Ags 
to which they can cause anergic or regulatory responses upon encounter with naïve T cells. 
These findings and the importance of iDCs in peripheral tolerance were supported by 
several discoveries, demonstrating the tolerogenic ability of iDCs both in vitro and in vivo. It 
has been shown that when DCs in their immature state are injected into the recipient, they 
can inhibit established effector T cell responses and contribute to generation of Tregs 
(Dhodapkar, Steinman et al. 2001). In addition, iDCs are well-known to induce IL-10-
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secreting Tr1-type Tregs in vitro after repetitive stimulation (Jonuleit, Schmitt et al. 2000). 
Recently, Ohnmacht et al. performed an ingenious experiment, where they depleted most 
crucial DC types (conventional DCs, plasmacytoid DCs and Langerhans DCs) from the mice 
using diphtheria toxin A (DTA) cross-breeding with CD11c-Cre mice. Such DC ablation 
resulted in development of spontaneous autoimmunity and high incline in the number of 
effector Th1 and Th17 cells (Ohnmacht, Pullner et al. 2009). 
3. Tolerogenic dendritic cells (TDCs) 
The long lasting perception of DC maturity and immaturity as two extremes of DC 
immunomodulatory function was enriched through recent years with several discoveries. 
These highlighted even further the unique functional plasticity of DCs as APCs, presenting 
facts that DCs can achieve alternative activation states under specific circumstances that 
grant them superior immunosuppressive properties. In this manner, TDCs possess several 
characteristics which separate them from iDCs. First and foremost, TDCs are equipped with 
active mechanisms to induce immune tolerance which we will outline below and can 
therefore achieve stronger immunosuppressive effects in shorter time periods.  
3.1 Immunosuppressive mechanisms of TDCs 
The stimulation of T cells by DCs is a finely orchestrated process involving the interplay of 
many factors starting with TCR engagement, interaction of various co-stimulatory 
molecules and the effect of soluble effector molecules produced by DCs, as well as T cells 
and surrounding tissues. Whenever the T cells are stimulated via TCR (signal 1) with absent 
or insufficient further stimuli, their activation results in T-cell unresponsiveness or even 
apoptosis (Steinman, Hawiger et al. 2003). Induction of tolerance by iDCs, due to their 
immature state, can therefore be viewed upon as passive induction of tolerogenic immune 
response due to lack of additional necessary stimuli required for optimal T cell activation.  
3.1.1 IDO competence 
In case of TDCs, the increased activity of enzyme indoleamine-2,3-dioxygenase (IDO) is one 
of major mechanisms contributing to TDC immunosuppressive function. IDO catabolizes 
tryptophan, thereby causing its depletion and the formation of bioactive kynurenine 
byproducts. Both local depletion of tryptophan, as well as formation of kynurenines have 
been shown to affect T cell proliferation and survival, since tryptophan itself represents an 
essential amino acid required for their growth (Grohmann, Fallarino et al. 2003). IDO is 
encoded by the IDO1 gene and its expression can be found at low levels in several tissues 
(i.e., gut, brain, thymus, etc.), however high expression of IDO is strictly regulated and can 
be found particularly in APCs, such as DCs, in response to IFN-┛, but can be induced by 
type I IFNs as well (IFN-┙ and IFN-┚) (Mellor and Munn 2004). Many studies have shown 
that IDO importantly regulates adaptive immune responses of T cells, thereby contributing 
to immune homeostasis. In animal models, the administration of 1-methyl-tryptophan, a 
small-molecule IDO inhibitor, into pregnant mice resulted in immediate rejection of an 
allogeneic fetus, confirming its role in maternal immune tolerance towards paternal 
alloantigens (Munn, Zhou et al. 1998; Mellor and Munn 2004). In this manner, it has been 
shown that IDO not only contributes to maternal tolerance but can control allograft rejection 
(Grohmann, Orabona et al. 2002; Cook, Bickerstaff et al. 2008) and ameliorate autoimmune 
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diseases as well (Grohmann, Fallarino et al. 2003; Platten, Ho et al. 2005). In addition, IDO-
mediated immunosuppression has been demonstrated to play a role in decreased 
immunosurveillance of tumor tissues and its inhibition by pharmacological agents such as 
1-L-methyl-tryptophan (1-MT) results in improved anti-tumor responses (Hou, Muller et al. 
2007). In the center of all such and similar scenarios, the DCs themselves seem to be the 
main discriminatory factor in IDO-mediated tolerance induction, which is in many cases 
associated with either paracrine or autocrine signaling by IFN-┛ (Grohmann, Bianchi et al. 
2000; Grohmann, Fallarino et al. 2003). In DCs, IDO can also be induced by the crosstalk 
between DCs and T cells. In this scenario, when the CD80 and CD86 molecules are engaged 
by inhibitory ligand CTLA-4 expressed on Tregs and also activated T cells, IDO is induced 
in a IFN-┛ fashion (Grohmann, Orabona et al. 2002; Fallarino, Grohmann et al. 2003), which 
strengthens the tolerogenic circuit and represents one of potential mechanisms through 
which DC tolerance is induced by interacting with Tregs. 
Increased IDO-competence in TDCs therefore produces its immunosuppressive effects in 
two major ways: either by tryptophan starvation (which can affect the responding T cells 
directly as well as mediate by-stander suppression due to local depletion (Grohmann, 
Fallarino et al. 2003) or by the effects of bioactive tryptophan metabolites. Tryptophan 
degradation by IDO results in formation of kynurenine (Kyn), which can be further 
catabolized to 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3-HAA) and 
quinolinic acid (Quin). These kynurenines were shown to possess a plethora of effects on 
various immune cells. For example, Kyn, 3-HK and 3-HAA can suppress the proliferation of 
T cells and Kyn also affects the proliferation of NK cells (Orabona and Grohmann 2011). 
Furthermore, kynurenines can cause apoptosis themselves, as 3-HAA induces the apoptosis 
of T cells in a pyruvate dehydrogenase kinase (PDK)-1- and Nf-┢B-dependent pathway 
(Hayashi, Mo et al. 2007). Also in several animal models, kynurenines and synthetic drugs 
similar to tryptophan catabolites, have ameliorated the severity of several immune-
mediated diseases including experimental autoimmune encephalomyelitis (EAE)(Platten, 
Ho et al. 2005), experimental asthma (Hayashi, Mo et al. 2007) and chronic granulomatous 
disease (Romani, Fallarino et al. 2008). 
3.1.2 Production of immunosuppressive cytokines 
In addition to low or absent production of IL-12p70, a cytokine directly involved in shaping 
of Th1-type immune responses (Vieira, de Jong et al. 2000), and in contrast to iDCs which 
are known to express low levels of both pro- and anti-inflammatory cytokines, the TDCs 
generated by various protocols produce high levels of anti-inflammatory cytokines, which 
play a major role in their superior tolerogenic capacity. Two major immunosuppressive 
cytokines produced by TDCs are IL-10 and TGF-┚. Dendritic cells isolated directly from 
specific anatomic compartments such as the Peyer patches, lungs, or the anterior chamber of 
the eye, produce increased quantities of IL-10 and drive the differentiation of IL-10-secreting 
Tregs or Tr1 cells (Lutz and Schuler 2002). Interleukin-10 was first identified as a cytokine 
synthesis inhibitory factor or CSIF, since it has been realized that it acts as a potent inhibitor 
of cytokine production by Th1 cells (Moore, Vieira et al. 1990). Today it is well known, that 
IL-10 is one of most general immunosuppressive biomolecules in our immune system with 
the ability to affect many immune cell types (Moore, de Waal Malefyt et al. 2001). 
Interleukin-10 down-regulates the expression of co-stimulatory and adhesion molecules, as 
well as the expression of MHC class II molecules and inflammatory cytokines (Fiorentino, 
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Zlotnik et al. 1991; Willems, Marchant et al. 1994). It modulates the stimulatory capacity of 
APCs and can induce anergy in both CD4+ and CD8+ T cells (Groux, O'Garra et al. 1997; 
Steinbrink, Wolfl et al. 1997; Allavena, Piemonti et al. 1998; Steinbrink, Graulich et al. 2002).  
In particular, the ability of TDCs to secrete large amounts of IL-10 has been directly 
associated with increased ability to induce Tr1 cells on many occasions. As stated above, 
iDCs have the potential to induce type 1 Tregs in vitro after repetitive stimulation(Jonuleit, 
Schmitt et al. 2000) and IL-10 is required for this process (Levings, Gregori et al. 2005). 
However, TDCs generated to produce high levels of IL-10 have been shown to do so more 
efficiently and in shorter time periods, inducing anergic T-cell lines after only one round of 
stimulation(Roncarolo, Gregori et al. 2006). Very recently, a new subset of IL-10-producing 
TDCs, termed DC-10, has been identified both in vivo and also induced in vitro (Gregori, 
Tomasoni et al. 2010). These DC-10 TDCs express high levels of inhibitory molecules, 
produce large amounts of IL-10 and have been shown especially efficient inducers of Tr1 
cells in an IL-10-dependent manner. 
Like IL-10, TGF-┚ can suppress such functions as IL-12 production and co-stimulatory 
molecule expression by APCs, such as macrophages and DCs (Takeuchi, Alard et al. 1998; 
Geissmann, Revy et al. 1999) and thereby inhibits Th1 type immune responses. It is also a 
crucial cytokine involved in immunosuppressive mechanisms of CD4+CD25+FoxP3+ Tregs 
and plays a role in their induction and proper function (Andersson, Tran et al. 2008; 
Sakaguchi, Yamaguchi et al. 2008). Today, a number of experimental data strongly support 
the correlation between induction of tolerance via TGF-┚, particularly in context of natural 
and peripherally induced FoxP3+ Tregs, and APCs, mainly the DCs(Belkaid and Oldenhove 
2008). In both humans and mice, DCs can induce FoxP3+ Tregs from naïve CD4+ T cells in 
the presence of TGF-┚. For example, in mice and rats, tumor cells have been shown to 
convert DCs into TGF-┚-secreting TDCs that later induce the proliferation of Tregs 
(Ghiringhelli, Puig et al. 2005). Subsets of Treg-inducing DCs can also be found and isolated 
under physiological conditions. In the intestine, mesenteric lymph node CD103+ DCs have 
been characterized with potential to readily induce FoxP3+ Tregs in a TGF-┚- and retionic 
acid (RA)-dependent manner (Coombes, Siddiqui et al. 2007). In addition, CD8+CD205+ DCs 
isolated from the spleen, preferentially produce TGF-┚ and their induction of FoxP3+ Tregs 
can be prevented by blocking anti-TGF-┚ (Yamazaki, Dudziak et al. 2008). 
3.1.3 Inhibitory molecules 
Another feature which adds to increased tolerogenic potential of TDCs is the surface 
expression of various inhibitory molecules which, in contrast to co-stimulatory molecules, 
deliver a negative signal to responding T cells and suppress their activation. Inhibitory 
molecules or sometimes referred to as co-inhibitory molecules, together with other signals 
derived from APCs, modulate and fine-tune the basic signaling through the TCR (signal 1). 
The discovery of inhibitory molecules and their understanding is just beginning to be 
understood and novel inhibitory candidates and their roles in DC-T cell communication are 
still being discovered. 
Within the B7 family of proteins, programmed death ligand (PD-L)1 and PD-L2 are 
expressed on DCs throughout different activation states and can also be induced on other 
APCs, such as monocytes (Schreiner, Mitsdoerffer et al. 2004; Meier, Bagchi et al. 2008). Both 
PD-L1 and PD-L2 bind to their mutual receptor, the programmed death-1 (PD-1) (Freeman, 
Long et al. 2000; Latchman, Wood et al. 2001). Engagement of PD-1 by PD-L1-Ig and PD-L2-
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Ig fusion proteins has an inhibitory effect on T cell proliferation and cytokine production 
upon TCR stimulation. The presence of PD-L1 and PD-L2 on human monocyte-derived DCs 
is important for the attenuation of T cell activation, since blockade of both inhibitory 
molecules results in increased T cell activation and cytokine production (Brown, Dorfman et 
al. 2003). 
Members of the immunoglobulin-like transcripts (ILT) family of proteins have been recently 
highlighted as important players in mechanisms of immune tolerance induction by DCs. 
Among these, the inhibitory receptors ILT3 and ILT4 have received most attention and have 
been recognized as an important descriptor of TDCs (Chang, Ciubotariu et al. 2002). 
Interaction of DCs with CD8+ suppressor cells (Ts) results in tolerization of the 
corresponding DCs with extensive up-regulation of ILT3 and ILT4 (Manavalan, Rossi et al. 
2003). Both ILT3 and ILT4 can be induced by immunosuppressive factors including IL-10 
and some pharmacological immunomodulators(Vlad, Piazza et al. 2003; Penna, Roncari et 
al. 2005; Svajger, Vidmar et al. 2008; Svajger, Obermajer et al. 2010). Manavalan et al. 
demonstrated that TDCs induced by IL-10 require ILT3 and ILT4 to induce tolerance in 
CD4+ T cells. Furthermore, newly discovered in vivo occurring TDC subset termed DC-10 
requires the ligation of ILT4 to its receptor HLA-G for effective induction of Tr1 regulatory 
cells (Gregori, Tomasoni et al. 2010). 
Another molecule important for peripheral immune homeostasis is a type II integral 
membrane protein belonging to the TNF superfamily called Fas ligand (FasL or CD95L) 
(Nagata and Golstein 1995). FasL is expressed on DCs and by interacting with its receptor 
Fas, it initiates a signaling cascade that leads to apoptotic cell death of cells bearing Fas. 
Apoptosis induced by Fas seems to play a pivotal role in T-cell homeostasis and control of 
cytotoxic T cell responses. In example, lymph node resident DCs in mice were shown to 
express functional FasL and serve as crucial regulators of CD8+ T cell responses during viral 
infection (Legge and Braciale 2005). 
3.2 Methods of TDC generation 
The term “alternative activation” has been used to describe the tolerogenic DC state and the 
name itself emphasizes the importance of DC activation state for its immunological 
function. The definition of “alternative activation” has mostly evolved through a number of 
in vitro/ex vivo based studies, exposing DC cultures to various biomolecules or 
pharmacological drugs with immunomodulatory potential, which in some cases resulted in 
a DC tolerization effect. Today, many protocols exist through which TDCs can be generated 
in the laboratory using different methods such as exposure to immunosuppressive cytokines 
or growth factors, immunosuppressive drugs or even by genetic modification of DCs to 
express immunosuppressive proteins.  
Use of immunsuppressive cytokines such as IL-10 in DC cultures was one of the first 
approaches to generate TDCs and it demonstrated the option of effectively manipulating 
DC function towards tolerance induction (De Smedt, Van Mechelen et al. 1997; Steinbrink, 
Wolfl et al. 1997). Interleukin-10-treated iDCs had a significantly reduced allo-stimulatory 
capacity and were resistant to maturation, as was shown by a down-regulation of co-
stimulatory molecules and an inability to induce effector T cell responses (Steinbrink, Wolfl 
et al. 1997). Furthermore, genetic engineering of DCs to express bioactive IL-10, using 
retroviral delivery system, results in DCs exhibiting extensive tolerogenic properties with 
significantly reduced capacity to induce allogeneic T cell proliferation and to generate 
cytotoxic T lymphocytes (CTLs) (Takayama, Nishioka et al. 1998). An important feature of 
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tolerogenic DCs induced by IL-10, besides anergy induction of responding CD4+ T cells, is 
their ability to generate regulatory T cells, which are then able to suppress activation and 
function of other T cells in an Ag-specific manner (Steinbrink, Graulich et al. 2002).  
The tolerogenic state of DCs can also be achieved with several other cytokines and 
biomolecules with potential immunosuppressive or pleiotropic properties such as 
transforming growth factor (TGF)-┚(Faunce, Terajewicz et al. 2004; Luo, Tarbell et al. 2007), 
interferon (IFN)-┙ (Carbonneil, Saidi et al. 2004), tumor necrosis factor (TNF)-┙(Verginis, Li 
et al. 2005), vasoactive intestinal peptide (VIP) (Chorny, Gonzalez-Rey et al. 2005), IL-16 in 
combination with thrombopoietin (Della Bella, Nicola et al. 2004) and IFN-┣ (Mennechet and 
Uze 2006). All of the above mentioned factors can influence DCs in an immunosuppressive 
fashion, either guiding their differentiation from blood precursors towards a tolerogenic cell 
type, or influencing the activation or maturation of already differentiated DCs. 
Many immunosuppressive drugs are known that induce DC tolerance by various 
mechanisms, frequently interfering with Nf-┢B activation or acting on multiple levels of Nf-
┢B signaling pathway, as well as on other kinases such as p38 MAPK, I┢B and others. For a 
critical reading on pharmacological TDC induction the reader is suggested to read focused 
review articles dedicated to the subject (Hackstein and Thomson 2004; Svajger, Obermajer et 
al. 2010). A classic example of DC maturation-inhibiting drugs are glucocorticoids (GCs) 
(Piemonti, Monti et al. 1999) and the activated form of vitamin D, 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3) (Piemonti, Monti et al. 2000). Glucocorticoids can inhibit the activity of Nf-┢B 
via enhanced transcription and synthesis of I┢B┙(Auphan, DiDonato et al. 1995; Scheinman, 
Cogswell et al. 1995), which binds to Nf-┢B in the cytoplasm and prevents its translocation 
to the nucleus or by direct association with the p65 Nf-┢B subunit (Scheinman, Gualberto et 
al. 1995). These effects are based on GCs binding to their respective nuclear receptor, the 
glucocorticoid receptor (GR)(Scheinman, Gualberto et al. 1995; De Bosscher, Vanden Berghe 
et al. 2000).  
Dendritic cells treated with dexamethasone (Dex) at nM concentrations prove resistant to 
maturation induced by TLR4 agonists, CD40L or TNF-┙(Piemonti, Monti et al. 1999; Xia, 
Peng et al. 2005). Similar effects can be observed with 1,25 (OH)2D3 (Berer, Stockl et al. 2000; 
Penna and Adorini 2000). Activation of DCs treated with either corticosteroids or 1,25 
(OH)2D3 leads to lowered expression of CD80, CD83, CD86 and both MHC class I and II 
molecules and display low allostimulatory capacity of responding T cells. After activation, 
such DCs show decreased production of IL-12, but produce great amounts of IL-10. The 
increased expression of IL-10 of activated TDCs most likely plays an important role in 
ensuring stable and maturation-resistant characteristics of treated DCs. Neutralization of IL-
10 using blocking mAbs during LPS-induced maturation of Dex-treated DCs allowed for 
partial maturation characterized by co-stimulatory molecule up-regulation (Xia, Peng et al. 
2005). Increased IL-10 expression of DCs treated with corticosteroids seems to be associated 
with increased ERK signaling. It has been demonstrated that Dex-treated DCs activated with 
LPS show significantly higher phosphorylation levels of ERK (Xia, Peng et al. 2005). It is also 
known that induction of glucocorticoid-induced leucine zipper (GILZ) induced by GCs 
interferes with Nf-┢B and MAPK/AP-1 signaling, preventing LPS-induced maturation of 
DCs, while at the same time up-regulates IL-10 production and expression of inhibitory 
molecule PDL-1 (Cohen, Mouly et al. 2006). Immunosuppression by 1,25(OH)2D3 is 
mediated by its nuclear receptor, the vitamin D receptor (VDR). Activation of VDR prevents 
DC maturation by inhibiting activity of Nf-┢B by direct suppression of relB promoter by 
VDR (Dong, Lutz et al. 2005), as well as by inhibiting Nf-┢B translocation, possibly by 
increasing stability of I┢B┙ (Szeto, Sun et al. 2007).  
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Mediator Type of 
immunomodulation
Mechanisms of 
suppression 
References 
Cytokines/Growth 
factors 
   
IL-10 Skewed maturation/ 
Differentiation, TDC 
induction 
T cell anergy, Treg 
cells 
(De Smedt, Van Mechelen et 
al. 1997; Steinbrink, Wolfl et 
al. 1997; Steinbrink, Graulich 
et al. 2002) 
TGF-ǃ TDC induction CD4+CD25+FoxP3+
Treg cells 
(Faunce, Terajewicz et al. 
2004; Luo, Tarbell et al. 2007) 
IFN-ǂ Skewed 
differentiation 
IL-10 production, 
naive CD4+ T cell 
apoptosis, Tr1 
cells 
(Carbonneil, Saidi et al. 2004) 
TNF-ǂ Semi-maturation CD4+CD25+FoxP3+
Treg cells 
(Verginis, Li et al. 2005) 
VIP Skewed 
differentiation, TDC 
induction 
Tr1 cells (Chorny, Gonzalez-Rey et al. 
2005) 
IL-16 + 
thrombopoietin 
Skewed 
differentiation, TDC 
induction 
T cell anergy (Della Bella, Nicola et al. 
2004) 
IFN-λ Skewed 
differentiation, TDC 
induction 
CD4+CD25+FoxP3+
Treg cells 
(Mennechet and Uze 2006) 
Pharmacological 
agents 
  (Svajger, Obermajer et al. 
2010) 
Glucocorticoids Inhibition of 
maturation/ 
differentiation 
T cell anergy, Treg 
cells 
(Piemonti, Monti et al. 1999; 
Xia, Peng et al. 2005) 
1,25(OH)2D3 Inhibition of 
maturation/ 
differentiation 
T cell anergy, Treg 
cells 
(Piemonti, Monti et al. 2000) 
LF15-0195 Inhibition of 
maturation 
T cell anergy (Yang, Bernier et al. 2003) 
Resveratrol Skewed 
differentiation, TDC 
induction 
Tr1 cells (Svajger, Obermajer et al., 
2010) 
Niflumic acid Inhibition of 
maturation 
low 
allostimulatory 
capacity 
(Svajger, Vidmar, et al. 2008) 
Table 1. Various mediators capable of inducing tolerogenic characteristics in DCs. 
LF15-0195 (LF) is a less toxic structural analog of an immunosuppressive agent 
15-deoxyspergualine. Incubation of DC cultures with LF prior to activation leads to general 
inhibition of the maturation process, characterized by low co-stimulatory molecule and 
IL-12 expression and the induction of Th2 immune response(Yang, Bernier et al. 2003). The 
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blockade of Nf-┢B activation by LF proceeds at the level of I┢B kinases (IKK), which 
normally phosphorylate I┢Bs to induce the release of Nf-┢B. LF inhibits IKK in a dose-
dependent manner, which results in abrogated nuclear translocation of Nf-┢B dimmers 
(Yang, Bernier et al. 2003). We have recently demonstrated that a natural polyphenol 
resveratrol, present pre-dominantly in red wine and grapes, substantially affects DC 
differentiation causing development of tolerogenic DCs, resistant to maturation and with 
the ability to induce IL-10-secreting Tr1-type cells (Svajger, Obermajer et al., 2010). In 
addition, a relatively unknown non-steroidal anti-inflammatory agent, niflumic acid, was 
demonstrated to suppress DC maturation with concomitant upregulation of inhibitory 
molecules (Svajger, Vidmar et al., 2008). 
4. Pre-clinical evaluation of TDCs 
The majority of clinical studies conducted on the use of DCs as therapeutic agents so far 
have been largely focused on DCs as tumor vaccines. In this context, the first report using a 
DC vaccine for treatment of patients with B-cell lymphoma was published 15 years ago in 
Nature Medicine (Hsu, Benike et al. 1996). With increased knowledge in immunosuppressive 
mechanisms gained throughout recent years, the use of TDCs as negative vaccines for 
various autoimmune diseases and allogeneic transplantations has also been relatively well-
studied in animal models. For this purpose, TDCs were generated by various means, either 
using pharmacological manipulation, administration of immunosuppressive cytokines, or 
even by genetic modification.  
4.1 TDCs in autoimmune disease studies 
4.1.1 Type 1 diabetes 
It is now recognized that unresolved inflammation is the loss of balance between 2 
biologically opposing arms of acute inflammation termed 'Yin' (pro-inflammatory) and 
'Yang' (anti-inflammatory) processes, as a basis for a wide range of chronic inflammatory as 
well as autoimmune diseases (Khatami 2008). Unresolved inflammation was further 
suggested to damage tissue integrity in immune-responsive and immune-privilege tissues 
causing acute and chronic inflammatory diseaases or even cancer (Khatami 2011). 
Tolerogenic DCs have been shown successful in prevention or amelioration of several 
autoimmune disease models. The non-obese diabetic (NOD) mouse model is frequently 
used to explore many aspects of insulin-dependent diabetes mellitus (IDDM) that is caused 
by the destruction of insulin-producing ┚-cells in the pancreas by the immune system 
(Atkinson and Leiter 1999). It has been shown that the active metabolite of vitamin D can 
induce TDCs that inhibits NOD mice diabetes development by increasing the function of 
Tregs (Adorini, Penna et al. 2003). Furthermore, DCs treated ex-vivo with IFN-┛, a 
pleiotropic cytokine with both immunostimulatory and immunoregulatory functions, act in 
an immunosuppressive manner after in vivo transfer (Shinomiya, Fazle Akbar et al. 1999). 
Such IFN-┛-treated TDCs were demonstrated to successfully migrate into the pancreas and 
associated lymphoid tissues, an important feature desired in the generation of both DCs as 
positive (tumor vaccines) and negative vaccination tools. Transfer of IFN-┛-treated TDCs 
prevented the onset of diabetes in 14 out of 19 mice recipients and afforded long-lasting 
protection against clinical and histological signs of IDDM (Shinomiya, Fazle Akbar et al. 
1999). In another approach, bone-marrow derived DCs were differentiated with either 
granulocyte macrophage colony stimulating factor (GM-CSF) + IL-4 or GM-CSF alone, to 
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generate DCs with low MHC class II and co-stimulatory molecule expression. Similarly to 
results obtained by this study, such DCs also had the capacity to migrate to the pancreas 
after intravenous injection (Feili-Hariri, Dong et al. 1999) and prevented the onset of IDDM 
with apparent induction Th1 to Th2 effector response switch.  
Additional growth factors were also studied for their capacity to generate TDCs with 
potential to treat immune-mediated conditions. The granulocyte-colony stimulating factor 
(G-CSF) was shown to possess immunoregulatory activity in association with the adaptive 
immune response in previous studies (Hartung, Docke et al. 1995; Mielcarek, Martin et al. 
1997; Sloand, Kim et al. 2000). Treatment of NOD mice with G-CSF resulted in protection 
from development of spontaneous diabetes and triggered the recruitment of 
immunosuppressive plasmacytoid DCs, that conferred tolerogenic outcome even upon 
transfer from G-CSF-treated, to vehicle-treated mice (Kared, Masson et al. 2005). Bone 
marrow-derived DCs from NOD mice have also been used to expand Ag-specific Tregs. As 
shown by Tarbell et al., DCs generated from NOD mice using GM-CSF and pulsed with 
single islet auto-antigen expanded CD4+CD25+ T cells with potent immunosuppressive 
activity (Tarbell, Yamazaki et al. 2004). This study showed that TDCs can also be used in a 
manner to generate/expand Ag-specific Tregs to subsequently suppress autoimmune 
diseases in vivo. 
4.1.2 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that mainly 
affects the synovial tissue of the joints. It has a complex pathogenesis with the involvement 
of many immune cell types, among which, the DCs seem to play an important role as APCs, 
as the importance of autoantigen presentation to potentially self-reactive CD4+ T cells has 
been emphasized on many occasions (Thomas, MacDonald et al. 1999). Considering the type 
of DCs, both myeloid, as well as plasmacytoid DCs have been found in blood of patients 
with RA, in the synovial fluid and in synovial tissue (Lebre and Tak 2009). Current 
biological treatments of RA include neutralization of cytokine products from APCs, namely 
TNF-┙, IL-1 and IL-6 (Khan, Greenberg et al. 2009). The emerging advanced therapies of RA 
exploit the tolerogenic capacity of TDCs and research is being focused on ex vivo 
manipulation of DC function and loading of DCs with respective Ags to later suppress 
autoimmune responses in vivo.  
Using genetically modified DCs expressing immunomodulating proteins, including IL-4, 
FasL and IDO, all resulted in significant regression of the established disease (Kim, Kim et 
al. 2001; Morita, Yang et al. 2001; Kim, Kim et al. 2002). In the case of DC-IL-4 and DC-IDO-
treated mice, more than half of treated subjects became disease-free for at least two months 
after treatment and the group using DC-FasL demonstrated a more transient amelioration of 
the disease (Kim, Kim et al. 2002). Animals that were treated with either DC-IL-4 or DC-
FasL responded with lowered IFN-┛ production from spleen-isolated lymphocytes and 
reduced T-cell proliferation after collagen stimulation. Such studies show the effectiveness 
of genetically modified DCs in therapeutic prevention of autoimmune diseases. 
Dendritic cells modulated with various pharmacological agents have also shown beneficial 
effects in RA. Treatment of DC progenitors with LF15-0195, an immunosuppressive drug 
with Nf-┢B inhibitory abilities, resulted in generation of TDCs characterized by low 
expression of MHC class II, CD40 and CD86 co-stimulatory molecules, as well as by poor 
allostimulatory capacity. Transfer of such TDCs into mice with collagen-induced arthritis 
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improved the clinical score of the disease and resulted in reduced Ab response against 
collagen (Popov, Li et al. 2006). Histological analysis of inflamed joints in treated mice 
revealed a decrease of inflammatory cell infiltration. Inhibition of Nf-┢B is a popular 
approach towards generating stable, maturation-resistant TDCs and another Nf-┢B 
inhibitor, BAY 11-7082 was also used in context of RA. Treatment of already established 
bone marrow-derived, Ag-pulsed DCs with BAY 11-7082 and their transfer into C57BL/6 
mice with antigen-induced arthritis yielded improved clinical score. This resolvement was 
dependent on IL-10 (Martin, Capini et al. 2007).  
In addition, TDC generation using dexamethasone yielded potent immunosuppressive DCs 
also effective in prevention of collagen-induced arthritis (van Duivenvoorde, Han et al. 
2007). The same study also evaluated the anti-arthritic activity of DCs treated with IL-10 and 
TNF-┙. While all immunomodulatory agents were able to modulate DC function in a way to 
prevent disease onset, they did so by different mechanisms. Both IL-10- and TNF-┙-treated 
DCs seemed to favor the shift of T cell effector response from Th1 to Th2, as evident by 
increased percentage of IL-5- and IL-10-secreting T cells and simultaneous reduction in 
IgG2a/IgG1 ratio in immunized mice (van Duivenvoorde, Han et al. 2007). On the other 
hand, dexamethasone treated DCs did not cause an increase in Th2 response and affected 
the Ab response in a non-specific manner. Rather, it seems that dexamethasone treated DCs 
cause an active suppression of Th1 immune responses, which corresponds to their 
tolerogenic effect. 
Interestingly, positive treatment of RA in animal models was also achieved using non-
modified DCs in their immature stage and surprisingly, even DCs treated with maturation 
stimuli such as TNF-┙ and TLR ligands. Similar to their ability to induce Tr1 regulatory T 
cells in vitro as described by Jonuleit (Jonuleit, Schmitt et al. 2000), repetitive injections of 
iDCs into mice with collagen-induced arhtirits triggered the expansion of regulatory T cells 
that protected the mice from the disease (Charbonnier, van Duivenvoorde et al. 2006). 
Tumor necrosis factor-┙ has been used in many experimental settings to generate DCs with 
beneficial effects in animal models of autoimmune disease, including RA disease models 
(van Duivenvoorde, Louis-Plence et al. 2004; Healy, Collins et al. 2008). Being a 
pro-inflammatory cytokine it seems paradoxical for TNF-┙ not to induce full DC activation. 
However, it has been shown that TNF-┙-treated DCs can obtain what is called a semi-
mature phenotype (increased expression of co-stimulatory molecules in the absence of IL-
12p70 production) and are able to act in an immunosuppressive manner, inducing the 
generation of IL-10 secreting Tregs in vivo (Lutz and Schuler 2002; Menges, Rossner et al. 
2002). Furthermore, it has been shown that DCs exposed to plasmid DNA or even short-
term to bacterial LPS (not more than 4 hours), yielded DCs with intermediate co-stimulatory 
molecule expression and low expression of pro-inflammatory cytokines (semi-mature). Such 
DCs both provided beneficial effects in histological and clinical score of collagen-induced 
arthritis in mice (Salazar, Aravena et al. 2008; Jaen, Rulle et al. 2009). 
4.1.3 Neuroimmunological disorders 
Multiple sclerosis (MS) is the most common inflammatory disease of the central nervous 
system (CNS), which is characterized by perivascular inflammatory lesions, demyelination 
and axonal damage (Steinman 1996). The animal model of MS is represented by 
experimental autoimmune encephalomyelitis or EAE and serves as a study model induced 
in susceptible rodent strains by active immunization with myelin Ags. In order for activated, 
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myelin-specific encephalitogenic CD4+ T cells to recognize their native protein, they must 
encounter their cognate APCs in the CNS to be re-activated. It has been shown that Ag 
presentation is not necessarily limited or due to CNS-resident microglia or astroglial cells, 
but that a population of DCs present in brain tissue is sufficient to present Ag to T cells and 
initiate disease development (Greter, Heppner et al. 2005), highlighting the importance of 
DCs as APCs in MS development. 
In an animal model using Lewis rats, iDCs have been used to induce tolerance to myelin 
basic protein (MBP)-specific immune responses. Immature, bone marrow-derived DCs 
from Lewis rats, pulsed with MBP in vitro and later injected back into animal subjects, 
conferred resistance to disease development upon active immunization of animals with 
MBP and Freund’s complete adjuvant (FCA)(Huang, Yang et al. 2000; Xiao, Huang et al. 
2001). The therapeutic effect of iDCs was compared with DCs treated with LPS, which did 
not induce tolerance, suggesting that the activation state of DCs is of crucial importance 
for their immunosuppressive efficiency. Since the efficiency of DC vaccines for therapy of 
autoimmune disorders largely relies on the identification of key self-Ags to be used for 
DC loading, scientists have found a way to avoid this tedious process in some cases. It has 
been demonstrated that bone-marrow derived DCs from rats already previously inflicted 
with EAE are seemingly “pulsed” in vivo. Generation of DCs from their bone marrow 
precursors in vitro can subsequently yield DCs that can later induce tolerance to EAE 
upon transfer into healthy subjects which are later immunized with MBP and FCA (Xiao, 
Huang et al. 2001).  
The potential of DC manipulation by various immunomodulatory factors has been 
demonstrated in the context of EAE. In this manner, it has been shown that IFN-┛ plays a 
vital role(Xiao, Wu et al. 2004). Splenic DCs that have been exposed in vitro to IFN-┛ exhibit 
therapeutic potential on acute EAE in Lewis rats as well as on chronic-relapsing EAE in B6 
and SJL/L mice. Administered, IFN-┛-treated DCs triggered Ag-specific production of IFN-
┛ and induced apoptosis of CD4+ T cells associated with increased IDO activity (Xiao, Wu et 
al. 2004). The reasons for implementing IFN-┛ in DC activation protocols for therapy of EAE 
seems logical from multiple viewpoints. Long-recognized as a primary activator of 
macrophages and primary Th1-driving cytokine, IFN-┛ is today seen as a pleiotropic 
cytokine, able to exert effects in both immunogenic and tolerogenic fashion (Zhang 2007). 
IFN-┛ is a strong inducer of some immunosuppressive characteristics in DCs, namely the 
activity of IDO enzyme which catabolizes tryptophan to cause tryptophan starvation and 
inhibition of T cell activation. In knockout models, mice deficient for IFN-┛ had an increased 
susceptibility to EAE and IFN-┛ was required for the expression of FoxP3 and the peripheral 
conversion of CD4+ Tregs in the course of EAE (Wang, Hong et al. 2006; Zhang 2007). 
4.2 TDCs in transplantation 
Although numerous reports demonstrate the effectiveness of immunosuppressive DCs 
(iDCs, TDCs, semi-mature DCs) in ameliorating or preventing the pathology of a given 
autoimmune disorder, even more research in recent years has been focused on tolerance 
induction by DCs in alloimmunity. Indeed, allogeneic transplantation offers some unique 
opportunities for DC manipulation that are not possible with autoimmune diseases. In a 
transplantation setting, there is some control over the introduction of donor alloantigens to 
the recipient, meaning that DCs can be manipulated before or after the initiation of the 
alloresponse. 
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Dendritic cells indeed play a pivotal role in both acute and chronic allograft rejection or 
acceptance (Morelli and Thomson 2007). After transplantation, the DCs, both that of donor 
and the recipient, present alloantigens to responding T cells through either the direct, 
indirect, or semi-direct mechanism. In direct presentation, the intact donor MHC molecules 
are presented to the recipient T cells by donor DCs present in the graft. In the indirect 
pathway, recipient DCs which have endocytosed and processed alloantigens, present the 
allopeptides on their own MHC molecules (Gould and Auchincloss 1999). Last through the 
semi-direct pathway, recipient T cells recognize intact MHC molecules that are transferred 
from donor cells to the surface of recipient DCs (Herrera, Golshayan et al. 2004). The direct 
pathway is considered to be the most powerful mechanism associated with acute graft 
rejection, but its influence decreases with time after transplantation. The indirect pathway 
on the other hand is characteristic of later time-points after transplantation and is 
considered to play the central role in so-called chronic rejection. 
The importance of DCs in allograft acceptance was clearly demonstrated more than 25 years 
ago, when a report was published demonstrating the prevention of murine islet allograft 
rejection by Ab-mediated depletion of donor DCs from the islets (Faustman, Steinman et al. 
1984). To this day, DCs have been manipulated using a number of pharmacological 
immunomodulators, immunosuppressive cytokines, as well as by genetic modification, to 
generate TDCs with the aim to establish long-term graft acceptance.  
Genetic modification of DCs to express immunosuppressive factors has been broadly 
applied in allogeneic transplantation models. Mouse bone marrow-derived DCs transfected 
with inhibitory molecule FasL displayed a marked increase in the capacity to induce 
apoptosis of Fas carrying responder cells and inhibited allogeneic T cell proliferation in vitro 
(Min, Gorczynski et al. 2000). Moreover, transfusion of FasL-expressing DCs into recipient 
mice prolonged the survival of fully MHC-mismatched cardiac allografts. In addition to 
inhibitory molecules, a number of studies reported on the successful treatment of allograft 
rejection using DCs transduced with immunosuppressive cytokines. Transduction of DCs to 
express IL-10 using adenoviral vectors, led to inhibition of DC mature phenotype and IL-12 
secretion. Portal venous infusion of 2x106 of IL-10-expressing DCs into animal recipients 7 
days before cardiac graft allotransplantation significantly prolonged the survival of 
allografts. Interestingly, in the same study, IL-10-expressing DCs administered through the 
tail vein failed to induce graft survival, highlighting the importance of vaccine delivery in 
transplantation settings (Zhang, Wang et al. 2004). Transforming growth factor-┚ is another 
molecule exploited for genetic manipulation of TDC generation. However, there seem to be 
some down-sides in using TGF-┚-expressing DCs in transplantation settings. In one case, 
DCs transduced to express TGF-┚1 showed pronounced in vitro immunosuppressive 
characteristics, but caused only a modest increase in allogeneic heart transplants (Takayama, 
Kaneko et al. 2002). In another study, TGF-┚-transduced DCs using adenoviral vectors 
caused prolonged survival of cardiac grafts in 67% of cases for more than 40 days. However, 
the administration of TGF-┚-expressing DCs caused fibrosis of the allografts which points to 
a limitation of using such DC-types in transplantation (Sun, Wang et al. 2002). Attempts 
have been made also to apply DCs transduced with constructs for both IL-10 and TGF-┚, 
which led to increased graft survival compared to single cytokine-expressing DCs 
(Gorczynski, Bransom et al. 2000). 
Several experimental data confirmed an essential role of IDO and DCs in immunoregulation 
of allo-responses (Hainz, Jurgens et al. 2007; Cook, Bickerstaff et al. 2008). In a rat kidney 
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transplantation model, allograft tolerance was induced by administration of an anti-CD28 
Ab (Haspot, Seveno et al. 2005). This in vivo tolerance could be broken when the animals 
were fed with IDO inhibitor 1-MT. Additional evidence was presented in transplantation 
studies using DCs with forced IDO expression. Pre-treatment of recipient mice with donor-
specific bone marrow-derived DCs genetically engineered to express IDO induced skin 
allograft survival along with reduced expression of crucial inflammatory cytokines by the 
recipient splenic T cells (Yu, Fang et al. 2008). 
It has been shown that graft rejection can be modulated by using non-modified, donor iDCs 
alone prior to transplantation (Fu, Li et al. 1996; Lu, Li et al. 1997). In addition, DC 
differentiation in the presence of GM-CSF and IL-4 at lower concentrations, results in 
generation of “semi-differentiated” adherent DCs with lower stimulatory capacity than their 
fully differentiated counterparts (Peche, Trinite et al. 2005). In this manner, such adherent 
DCs administered just one day prior to transplantation induced significant prolongation of 
heart allograft survival and suppressed anti-donor humoral and cellular immune responses 
(Peche, Trinite et al. 2005). In this manner, improper or insufficient DC differentiation 
clearly contributes to generation of APCs with low stimulatory capacity suitable for cell 
therapy studies. Similarly, Lutz et al. generated DCs in the presence of low dose GM-CSF, 
but without additional IL-4. Such DCs were comparable to standard bone marrow-derived 
DCs in their Ag-presenting capacity, but expressed an immature phenotype and proved 
maturation-resistant to various stimuli including LPS, CD40 ligand or TNF-┙ (Lutz, Suri et 
al. 2000). When transferred to recipient mice 7 days before transplatation, low GM-CSF-
generated DCs induced cardiac allograft survival up to 100 days post-op (Lutz, Suri et al. 
2000). 
Due to their superior tolerogenic potential, TDCs have been generated by various means 
with the aim to treat allograft rejection. Since the local tissue environment in a 
transplantation setting represents a highly inflammatory site, many endogenously released 
inflammatory factors could have the potential to activate donor or recipient DCs and 
increasing their immunostimulatory functions. For this purpose, DCs have been made 
maturation resistant by blockade of Nf-┢B as the central transcription pathway involved in 
DC maturation (Yoshimura, Bondeson et al. 2001). Using Nf-┢B decoy 
oligodeoxyribonucleotides (ODNs), the NF-┢B activity and associated expression of co-
stimulatory molecules and cytokines can be suppressed, rendering such DCs tolerogenic 
and resistant to maturation. Infusion of NF-┢B ODN-modified bone marrow-derived DCs 
into allogeneic recipients prior to cardiac transplantation resulted in significant prolongation 
of allograft survival without additional immunosuppression by classical immunosuppressive 
drugs (Giannoukakis, Bonham et al. 2000; Tiao, Lu et al. 2005). Similar results were obtained 
when Nf-┢B ODN-modified DCs were used in a liver transplantation model (Xu, Suo et al. 
2004).  
Certain pharmacological immunosuppressants have proved valuable tools for TDC 
generation and have been used in preparation of TDCs as cell therapy tools in 
transplantation. Rapamycin (or sirolimus) is a widely-known immunosuppressant drug 
used to treat rejection in organ transplantation, particularly for kidney transplants, and has 
been in use since 2001 (Hackstein and Thomson 2004). Rapamycin inhibits downstream 
signaling from the mammalian targets of rapamycin (mTOR) proteins by forming complexes 
with its intracellular receptor FK506-binding protein 12 (FKBP12)(Sehgal 1998). Rapamycin 
does not affect the development or differentiation of DCs from their precursors in a 
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qualitative manner, like for example corticosteroids, but significantly impairs DC-mediated 
Ag-uptake and inhibits DC maturation to some extent (Hackstein and Thomson 2004). In 
terms of indirect pathway of alloantigen recognition as described above, rapamycin-treated, 
recipient DCs can induce Ag-specific modulation of T cell functions and prolong allograft 
survival, when pulsed with alloantigen (Taner, Hackstein et al. 2005). Recently, it was 
demonstrated that rapamycin impairs the maturation of DCs and their ability to stimulate 
allogeneic T cells, but empowers such DCs to stimulate and expand murine alloantigen-
specific CD4+CD25+FoxP3+ Tregs (Taner, Hackstein et al. 2005). In light of indirect 
allorecognition, infusion of recipient, rapamycin-treated DCs pulsed with alloantigen prior 
to transplantation, followed by a low-rapamycin postoperative course, resulted in tolerance 
establishment to allogeneic graft and indefinite survival of cardiac graft(Turnquist, 
Raimondi et al. 2007). 
5. Human clinical trials using TDCs 
At the moment, it is a bit difficult to constructively discuss any potential results from human 
clinical studies using TDCs because until very recently, no results have been published on 
any aspect of their use in humans. However, at the time of writing this chapter, in June 2011, 
a group from University of Pittsburgh published their first results from a phase I safety 
study using TDCs in type 1 diabetic patients (Giannoukakis, Phillips et al. 2011). The intent 
of the study was to confirm the safety of DC use in autoimmune disease patients, 
particularly with type I diabetes. The study included a total of 10 patients between 18 and 60 
years of age, without otherwise known or suspected health conditions. The patients received 
autologous DCs either unmanipulated or directed ex vivo towards an immunosuppressive 
state and 106 DCs were administered intradermally in the abdomen every 2 weeks for total 
of four administrations. Although the study did not demonstrate extensive beneficial effects 
of DC treatments (based upon measurements of patient glucose and glycated HbA1c levels 
in blood, as well as C peptide concentrations in serum), the use of autologous DCs proved 
safe and was well tolerated in adult type 1 diabetic patients (Giannoukakis, Phillips et al. 
2011). Indeed, cancer vaccine-associated clinical studies greatly outnumber ones with TDCs 
and along with numerous existing pre-clinical data, can give a relatively good picture of 
what can be expected in the near future. In immunology in general, it is extremely difficult 
to study humans, so any information that can be extrapolated from related studies is of 
great worth. One thing that has been learned from cancer vaccine trials, and confirmed 
recently by Giannoukakis et al. (Giannoukakis, Phillips et al. 2011), is that autologous 
human DC vaccines can be safe and cause minimal side effects. They also confirm that 
previously observed adverse events such as elevated levels of pro-inflammatory cytokines, 
fever, chills and general malaise, associated with DC-therapy studies are due to priming of 
patients with cytokines such as IL-2 and granulocyte-monocyte colony-stimulating factor 
(Correale, Campoccia et al. 2001; Dhodapkar, Steinman et al. 2001). Another encouragement 
comes from the successful completion of growing number of phase III trials (source – NIH), 
crowned by the first approved cellular immunotherapy in April, 2010, by the US Food and 
Drug Administration (FDA)(Cheever and Higano 2011).  
At the time being, almost everything we know about vaccination and therapy using TDCs, 
comes from rodent models or in vitro-based studies. We are currently at the stage where the 
tolerogenic mechanisms of TDCs are beginning to be relatively well understood and a 
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decent number of protocols for their generation have been developed in the recent years. 
However, a number of issues related to human studies exist, that have not been sufficiently 
addressed. The beginning human trials using TDCs thus carry the task of answering many 
of these questions in the years to come, since direct extrapolation to humans from animal 
models is impossible. The most important matters that need resolving are:  
 What DC type is to be used for particular treatments (iDCs, semi-mature DCs, various 
TDC types produced by different approaches) 
 Generation of standardized protocols for DC generation corresponding to the strict 
good manufacturing practice (GMP) standards 
 What is the proper number of cells to be used in a single application 
 What is the ideal route and frequency of DC delivery  
 What are the crucial antigens to be presented by DCs 
 Will negative vaccination with DCs prove sufficient, or will it come down to 
combinatorial therapies to achieve long-term success 
As of May this year, a second clinical trial using DCs for negative vaccination was registered 
within the National institutes of Health (NIH) for phase I study, proceeding at the 
Newcastle University. The study aims to look at the safety, feasibility and acceptability of 
TDC therapy for patients suffering from RA. The therapeutic will represent autologous 
TDCs, derived from the patients peripheral blood leukocytes by leukapheresis and ex vivo 
culture and intends to include 12 patients in total. Patients will be chosen for their RA 
pathology and at least one swollen knee joint. The DCs will be administered directly into the 
knee joint and observed by arthroscopy for disease assessment (source – NIH). 
6. Concluding remarks 
Undeniable progress has been made in the field of therapeutic tolerance induction using 
immunosuppressive DCs, and there is an evolving pool of knowledge that we hope will 
perpetuate clinical research in the future. We now know much about how DCs exercise their 
tolerogenic function, both to auto- or allo-antigens, and of the way how to modulate DC 
function in the laboratory. However, some crucial matters need to be resolved on how will 
these cells behave once applied into the human body. In addition, the challenge awaits on 
how can we fine-tune the process ranging from TDC generation to their application and 
observing the clinical score, while at the same time meeting the quality standards required 
without risking excessive funds.  
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